(Q46925948)

26 December 2017

title

A novel IkappaB kinase-beta inhibitor ameliorates bleomycin-induced pulmonary fibrosis in mice (English)

1 reference

26 December 2017

1 reference

Mami Inayama

1

1 reference

26 December 2017

Yasuhiko Nishioka

2

1 reference

26 December 2017

Momoyo Azuma

3

1 reference

26 December 2017

Susumu Muto

4

1 reference

26 December 2017

Yoshinori Aono

5

1 reference

26 December 2017

Hideki Makino

6

1 reference

26 December 2017

Kenji Tani

7

1 reference

26 December 2017

Hisanori Uehara

8

1 reference

26 December 2017

Keisuke Izumi

9

1 reference

26 December 2017

Akiko Itai

10

1 reference

26 December 2017

Saburo Sone

11

1 reference

26 December 2017

language of work or name

English

0 references

publication date

2 February 2006

1 reference

26 December 2017

American Journal of Respiratory and Critical Care Medicine

published in

1 reference

26 December 2017

volume

173

1 reference

26 December 2017

issue

9

1 reference

26 December 2017

page(s)

1016-1022

1 reference

26 December 2017

Idiopathic Pulmonary Fibrosis

cites work

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200506-947OC

Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200506-947OC

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200506-947OC

Acute interstitial pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200506-947OC

Demystifying idiopathic interstitial pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200506-947OC

Cytoplasmic deposition of NFkappaB decoy oligonucleotides is insufficient to inhibit bleomycin-induced pulmonary inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200506-947OC

The role of nuclear factor-kappa B in pulmonary diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200506-947OC

IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200506-947OC

IkappaB kinase-beta: NF-kappaB activation and complex formation with IkappaB kinase-alpha and NIK

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200506-947OC

Abnormal morphogenesis but intact IKK activation in mice lacking the IKKalpha subunit of IkappaB kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200506-947OC

Severe liver degeneration in mice lacking the IkappaB kinase 2 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200506-947OC

Antioxidant intake in pregnancy in relation to wheeze and eczema in the first two years of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200506-947OC

Inhibition of IkappaB phosphorylation in cardiomyocytes attenuates myocardial ischemia/reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200506-947OC

A novel NF-kappaB inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200506-947OC

Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200506-947OC

Simple method of estimating severity of pulmonary fibrosis on a numerical scale

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200506-947OC

Development of a sensitive multi-well colorimetric assay for active NFkappaB

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200506-947OC

Molecular mechanisms of glucocorticoid action: what is important?

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200506-947OC

Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200506-947OC

10.1164/RCCM.200506-947OC

21 January 2018

Identifiers

DOI

1 reference

26 December 2017

release_fymrw3k4izgh5ikzzwajkkcm64

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/fymrw3k4izgh5ikzzwajkkcm64

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

26 December 2017